CD133 serves as a valuable target in NSCLC treatment, as therapies like TClC can inhibit CD133-positive stem-like cells, thereby reducing tumor growth, EMT, migration, invasion, and oncogenic factor secretion, ultimately disrupting tumor progression. Here, PROM1 is linked to neoplasm.